Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 30, 2015 1:54 AM ET

Company Overview of The Multiple Myeloma Research Foundation, Inc

Company Overview


United States

Founded in 1998

Key Executives for The Multiple Myeloma Research Foundation, Inc

Chief Executive Officer, President and Chief Operating Officer
Age: 49
Founder and Executive Chairman
Age: 55
Age: 59
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2014.

The Multiple Myeloma Research Foundation, Inc Key Developments

The Multiple Myeloma Research Foundation Appoints Wynton Marsalis to Honorary Board of Directors

The Multiple Myeloma Research Foundation (MMRF) announced that Managing and Artistic Director of Jazz at Lincoln Center, Wynton Marsalis has joined the MMRF Honorary Board.

The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM

The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Daniel Auclair, Vice President, Translational Research.

Inflection Biosciences Ltd Announces Collaboration with The Multiple Myeloma Research Foundation

Inflection Biosciences Ltd. announced a collaboration with the Multiple Myeloma Research Foundation on pre-clinical testing of its innovative dual mechanism PIM/PI3K inhibitor IBL-202. PIM and PI3K are two key regulators in signalling pathways that have proved essential for the proliferation and survival of myeloma cells. The MMRF investigators will test the effectiveness of IBL-202 alone and in combination with other therapeutics in pre-clinical models of multiple myeloma. These models are recognised to be predictive of clinical efficacy in cancer patients with multiple myeloma. IBL-202 is a dual mechanism kinase inhibitor that selectively inhibits PIM and PI3K without affecting the activity of other kinases. MMRF support will greatly assist in further evaluating the potential of IBL-202 for patients with multiple myeloma, one of the many indications hope to consider. The MMRF is working with Inflection Biosciences through its Translational Network of Excellence program, which supports critical research at leading academic medical centers focused on promising investigational therapies for multiple myeloma.

Similar Private Companies By Industry

Company Name Region
Jervis Afanasiff & Redinger United States
Ellis Partners LLC United States
Midwest Affordable Housing 1997-1, L.L.C. United States
Laredo Federal Credit Union United States
Imaging Science Technologies Radiation Blocking Division Inc United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Multiple Myeloma Research Foundation, Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at